To Switch or not to Switch to Long-acting Injectable Cabotegravir/Rilpivirine in PWH With Past Hepatitis B Virus (HBV) Coinfection: Which HBV Markers to Manage Risk of HBV Reactivation?
We report the occurrence of low-level hepatitis B virus (HBV) viremia in people with HIV with controlled CD4 counts and isolated core antibody reactivity switched to long-acting injectable cabotegravir/rilpivirine. This series raises questions about the reintroduction of anti-HBV medications, presents the variation of several HBV markers alongside HBV-DNA and reveals an effective spontaneous immune response.
Authors
- Vincent Thibault
- David Chirio (ORCID: https://orcid.org/0000-0002-7186-2818)
- Laurence Ollier
- Pascal Puglièse
- Alissa Naqvi
- Michel Carles
- Anne De Monte
- J. Durant
Institutions
- 3M (United States) (US)
- Inserm (FR)
- Université Côte d'Azur (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Centre Hospitalier Universitaire de Rennes (FR)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1093/ofid/ofaf266
- Citations
- 4
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.42